Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting.

Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting.

HCV protease inhibitors (PIs) boceprevir and telaprevir in combination with PEG-Interferon alfa and Ribavirin (P/R) is the new standard of care in the treatment of chronic HCV genotype 1 (GT1) infection. However, not every HCV GT1 infected patient is eligible for P/R/PI therapy. Furthermore phase II...

Full description

Bibliographic Details
Main Authors: Benjamin Maasoumy, Kerstin Port, Antoaneta Angelova Markova, Beatriz Calle Serrano, Magdalena Rogalska-Taranta, Lisa Sollik, Carola Mix, Janina Kirschner, Michael P Manns, Heiner Wedemeyer, Markus Cornberg
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3562338?pdf=render

Internet

http://europepmc.org/articles/PMC3562338?pdf=render

Similar Items